Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors

2005 ◽  
Vol 58 (1) ◽  
pp. 107-116 ◽  
Author(s):  
Joseph P. Eder ◽  
David P. Ryan ◽  
Leonard Appleman ◽  
Andrew X. Zhu ◽  
Thomas Puchalski ◽  
...  
2004 ◽  
Vol 10 (7) ◽  
pp. 2222-2230 ◽  
Author(s):  
David P. Ryan ◽  
Joseph P. Eder ◽  
Thomas Puchlaski ◽  
Michael V. Seiden ◽  
Thomas J. Lynch ◽  
...  

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 2558-2558 ◽  
Author(s):  
Jennifer Rachel Eads ◽  
Smitha S. Krishnamurthi ◽  
Joel N. Saltzman ◽  
Neal J. Meropol ◽  
Joseph A. Bokar ◽  
...  

2015 ◽  
Vol 22 (6) ◽  
pp. 1364-1370 ◽  
Author(s):  
Melinda S. Merchant ◽  
Matthew Wright ◽  
Kristin Baird ◽  
Leonard H. Wexler ◽  
Carlos Rodriguez-Galindo ◽  
...  

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 3029-3029 ◽  
Author(s):  
J. Dupont ◽  
M. L. Rothenberg ◽  
D. R. Spriggs ◽  
J. M. Cedarbaum ◽  
E. S. Furfine ◽  
...  

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 2537-2537 ◽  
Author(s):  
P. A. Cohen ◽  
D. W. Northfelt ◽  
G. J. Weiss ◽  
D. D. Von Hoff ◽  
K. Manjarrez ◽  
...  

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 2562-2562 ◽  
Author(s):  
Jennifer Rachel Eads ◽  
Smitha S. Krishnamurthi ◽  
Joel N. Saltzman ◽  
David Lawrence Bajor ◽  
Shaveta Vinayak ◽  
...  

2014 ◽  
Vol 25 ◽  
pp. iv153 ◽  
Author(s):  
T. Yokota ◽  
T. Tsushima ◽  
H. Kenmotsu ◽  
J. Watanabe ◽  
M. Endo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document